Zifanocycline (KBP-7072) TFA is an orally active, semi-synthetic aminomethylcycline antibiotic that inhibits the normal function of bacterial ribosomes. Zifanocycline TFA has broad spectrum in vitro antimicrobial activity against Gram-positive and Gram-negative bacteria, including many multidrug-resistant pathogens. Zifanocycline TFA is indicated for the study of acute bacterial skin and skin structure infections, community-acquired bacterial pneumonia, and complicated intra-abdominal infections.
References:
[1]. Tan X, et al. Nonclinical Pharmacokinetics, Protein Binding, and Elimination of KBP-7072, an Aminomethylcycline Antibiotic, in Animal Models. Antimicrob Agents Chemother. 2020;64(6):e00488-20. Published 2020 May 21.
[2]. Lepak AJ, et al. Pharmacokinetic/Pharmacodynamic Evaluation of a Novel Aminomethylcycline Antibiotic, KBP-7072, in the Neutropenic Murine Pneumonia Model against Staphylococcus aureus and Streptococcus pneumoniae. Antimicrob Agents Chemother. 2019;63(3):e02404-18. Published 2019 Feb 26.